China creates new regulatory pathway to accelerate access to advanced biomedical therapies

Summary

China has established a new regulatory "tech track" for advanced therapies like personalized cancer treatments, cell and gene therapies, and regenerative medicine that don't fit traditional drug approval pathways. This first-in-the-world regulation aims to give Chinese patients faster access to emerging biomedical innovations. While it promises to accelerate access for local patients, the policy may also change the licensing landscape for foreign companies seeking to bring their advanced therapies to the Chinese market.